Supernus Pharmaceuticals vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Supernus Pharmaceuticals Inc (SUPN)

Q3 202623 Jun – 20 Aug 2026

▲2

Supernus- Indivior merger reshapes CNS pharma, Q2 revenue beats

All-stock merger with Indivior Supernus agreed to merge with Indivior in an all-stock deal, creating a CNS-focused company with $2.2B pro forma revenue and $125M cost synergies. Supernus shareholders get 1.5401 Indivior shares per share. The combined firm keeps the SUPN ticker and CEO. This is the main driver, boosting scale and pipeline.
The merger is the biggest new event, directly reshaping Supernus and driving the stock's recent surge.
Q2 revenue beat and strong growth Supernus reported Q2 revenue of $211.3 million, up 27.7% year over year and 2.8% above estimates. This shows the core business is growing faster than expected, supporting the stock price.
The Q2 revenue beat is new and confirms operational strength, a key fundamental driver.

July 202623 Jun – 20 Aug 2026

▲2

Supernus- Indivior merger reshapes CNS pharma, Q2 revenue beats

All-stock merger with Indivior Supernus agreed to merge with Indivior in an all-stock deal, creating a CNS-focused company with $2.2B pro forma revenue and $125M cost synergies. Supernus shareholders get 1.5401 Indivior shares per share. The combined firm keeps the SUPN ticker and CEO. This is the main driver, boosting scale and pipeline.
The merger is the biggest new event, directly reshaping Supernus and driving the stock's recent surge.
Q2 revenue beat and strong growth Supernus reported Q2 revenue of $211.3 million, up 27.7% year over year and 2.8% above estimates. This shows the core business is growing faster than expected, supporting the stock price.
The Q2 revenue beat is new and confirms operational strength, a key fundamental driver.

Latest23 Jun – 20 Aug 2026

▲2

Supernus- Indivior merger reshapes CNS pharma, Q2 revenue beats

All-stock merger with Indivior Supernus agreed to merge with Indivior in an all-stock deal, creating a CNS-focused company with $2.2B pro forma revenue and $125M cost synergies. Supernus shareholders get 1.5401 Indivior shares per share. The combined firm keeps the SUPN ticker and CEO. This is the main driver, boosting scale and pipeline.
The merger is the biggest new event, directly reshaping Supernus and driving the stock's recent surge.
Q2 revenue beat and strong growth Supernus reported Q2 revenue of $211.3 million, up 27.7% year over year and 2.8% above estimates. This shows the core business is growing faster than expected, supporting the stock price.
The Q2 revenue beat is new and confirms operational strength, a key fundamental driver.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.